Successful use of long acting octreotide in two cases with Beckwith-Wiedemann syndrome and severe hypoglycemia

International Journal of Pediatric Endocrinology

Ron S Newfield¹  Michael E Gottschalk¹  Hiba Al-Zubeidi¹ 

[1] Pediatrics, University of California, San Diego, San Diego, CA, USA

关键词: Beckwith-Wiedemann syndrome;    Hyperinsulinism;    Hypoglycemia;   

Others  :  1135801
DOI  :  10.1186/1687-9856-2014-18

 received in 2014-05-11, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Introduction

Hyperinsulinism associated with Beckwith-Wiedemann syndrome (BWS) can occur in about 50% of cases, causing hypoglycemia of variable severity. Parenteral use of octreotide may be indicated if unresponsive to diazoxide. There is limited data on use of octreotide in BWS.

Objective

Chart review describing 2 cases with BWS and hypoglycemia treated with long acting Octreotide as a monthly injection.

Cases

We describe two unrelated females born large for gestational age found to have clinical features consistent with BWS, who developed severe hypoglycemia. Genetic diagnosis of BWS was confirmed. The first patient was born at 37 weeks and developed hypoglycemia shortly after birth. She was initially started on diazoxide but developed pulmonary congestion and was therefore switched to depot octreotide (LAR). She maintained euglycemia with LAR. In the second patient (born at 26-4/7 weeks), onset of hypoglycemia was delayed till 11 weeks of age due to hydrocortisone (indicated hemodynamically) and continuous feeding, and was partially responsive to diazoxide. She was switched to octreotide 4 times daily, treated till at age 18 months. Despite frequent feeds, she required treatment again between ages 4–6.5 years, initially with diazoxide but due to severe hypertrichosis she was switched to LAR with an excellent response. Both patients treated with LAR for over two years achieved euglycemia above 70 mg/dl and had normal height gain, without side effects.

Conclusion

Successful treatment of hypoglycemia can be achieved and maintained with LAR in infants and children with BWS who are either resistant or cannot tolerate diazoxide.

【 授权许可】

   
2014 Al-Zubeidi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Weng E, Mortier G, Graham J: Beckwith-Wiedemann syndrome. Clin Pediatric (Phila) 1995, 34:317-326.
• [2]Spivey PS, Bradshaw WT: Recognition and management of the infant with Beckwith-Wiedemann Syndrome. Adv Neonatal Care 2009, 9(6):279-284. quiz 285
• [3]Munns CFJ, Batch JA: Hyperinsulinism and Beckwith-Wiedemann Syndrome. Arch Dis Child Fetal Neonatal Ed 2001, 84:F67-F69.
• [4]Elliott M, Bayly R, Cole T, Temple IK, Maher ER: Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet 1994, 46(2):168-174.
• [5]Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Bliek J, Schofield PN, Reik W, Macdonald F, Maher ER: Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005, 13(9):1025.
• [6]Enklaar T, Zabel BU, Prawitt D: Beckwith-Wiedemann syndrome: multiple molecular mechanisms. Expert Rev Mol Med 2006, 8(17):1.
• [7]Hussain K, Cosgrove KE, Shepherd RM, Luharia A, Smith VV, Kassem S, Gregory JW, Sivaprasadarao A, Christensen HT, Jacobsen BB, Brusgaard K, Glaser B, Maher EA, Lindley KJ, Hindmarsh P, Dattani M, Dunne MJ: Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphate-sensitive potassium channels. J Clin Endocrinol Metab 2005, 90(7):4376-4382. Epub 2005 Apr 5
• [8]Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanné-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P: Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012, 166(2):333-339.
• [9]Modan Moses D, Koren I, Mazor Aronovitch K, Pinhas Hamiel O, Landau H: Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011, 96(8):2312.
• [10]Gerver WJ, Menheere PP, Schaap C, Degraeuwe P: The effects of Somtostatin analogue on the metabolism of an infant with beckwith-Wiedemann Syndrome and hyperinsulinaemic hypoglycemia. Eur J Pediatric 1991, 150:634-637.
• [11]DeBaun MR, King AA, White N: Hypoglycemia in Beckwith–Wiedemann syndrome. Semin Perinatol 2000, 24:164-171.
• [12]Zarate YA, Shur N, Robin A, Garnica AD, Quintos JB, Schaefer GB: Persistent congenital hyperinsulinism in two patients with Beckwith-Wiedemann syndrome due to mosaic uniparental disomy 11p. J Pediatr Endocrinol Metab 2014. Epub ahead of print (doi:10.1515/jpem-2013-0484)
• [13]Mohamed Z, Arya VB, Hussain K: Hyperinsulinaemic Hypoglycaemia: Genetic Mechanisms, Diagnosis and Management. J Clin Res Pediatr Endocrinol 2012, 4(4):169-181.
• [14]Laje P, Palladino AA, Bhatti TR, States LJ, Stanley CA, Adzick NS: Pancreatic surgery in infants with Beckwith–Wiedemann Syndrome and Hyperinsulinism. J Pediatr Surg 2013, 48:2511-2516.
• [15]Aynsley-Green A, Hussain K, Hall J: Practical management of hyperinsulinsism in infancy. Arch Dis Child Fetal Neonatal Ed 2000, 82:F98-F107.